Delayed musculoskeletal symptoms after breast radiotherapy can reflect osteoradionecrosis rather than recurrence, thus ...

In BREAKWATER, EC plus FOLFIRI achieved a 64.4% response rate and showed a trend toward improved overall survival in patients ...

Pfizer Inc. (NYSE: PFE) today announced positive results from Cohort 3, a separate randomized cohort of the pivotal BREAKWATER trial, evaluating ...

Pfizer Inc. today announced positive results from Cohort 3, a separate randomized cohort of the pivotal BREAKWATER trial, ...

This case describes a woman in her mid-40s with recurrent colorectal cancer who developed severe dermatologic toxicity during ...

With durable responses, encouraging survival outcomes, and evidence that some patients may become eligible for ...

The Palm Beaches are redefining relaxation with a wave of fresh spa experiences and innovative wellness offerings. From cutting-edge treatments at newly renovated resorts to immersive mind-body ...

In October 2025, Case Comprehensive Cancer Center announced a clinical trial is to see if shorter Photodynamic Therapy (PDT) ...

Over 70 percent of patients in the first-line subgroup responded to amivantamab plus chemotherapy with most responses lasting beyond 16 monthsNotable ...

Over 70 percent of patients in the first-line subgroup responded to amivantamab plus chemotherapy with most responses lasting beyond 16 months Notable responses were ...

Lauren Goodman, a registered nurse at Juliana Clinics in Beverly Hills, says she’s had people traveling from around the US to ...

In-office treatments are expensive, time-consuming, and realistically not something most of us can book as often as ...